| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3475 | Mri-1891 | Novel peripheral CB1R antagonist, being highly biased toward inhibiting CB1R-induced β-arrestin-2 (βArr2) recruitment over G-protein activation |
|
| DCC3476 | Mrl-248 | Novel potent and selective RORγT inhibitor, showing no appreciable activity against a panel of related nuclear hormone receptors |
|
| DCC3477 | Mrl-299 | Novel potent RORγT inhibitor |
|
| DCC3478 | Mrl-367 | Novel potent and selective RORγT inhibitor, showing no appreciable activity against a panel of related nuclear hormone receptors |
|
| DCC3479 | Mrl-770 | Novel selective and reproducible inhibitor of DNA synthesis in E. coli JL553 |
|
| DCC3480 | Mrs2220 | Selective enhancer of the ATP effects at fast desensitizing P2X (P2X1 and P2X3) receptors |
|
| DCC3481 | mrs2690 | Potent P2Y14 receptor agonist |
|
| DCC3482 | mrs2693 Trisodium | Selective P2Y6 agonist |
|
| DCC3483 | mrs2768 | Selective P2Y2 agonist |
|
| DCC3484 | mrs2957 | Potent P2Y6 agonist |
|
| DCC3485 | Mrs2964 | Potent and selective P2Y6 receptor agonist |
|
| DCC3486 | Mrs4598 | Novel highly potent human CD73 inhibitor (K i = 0.673 nM) |
|
| DCC3487 | Mrs4608 | Novel potent antagonist of P2Y 14 receptor (P2Y 14 R) (IC 50 ~20 nM at hP2Y 14 R/mP2Y 14 R) |
|
| DCC3488 | Mrs4654 | Novel potent P2Y14 Receptor Antagonist (IC 50 , 15 nM) |
|
| DCC3489 | Mrs7396 | Bitopic fluorescent antagonist of the A2A adenosine receptor |
|
| DCC3490 | Mrs7469 | Novel highly selective A1 adenosine receptor (A1AR) agonist |
|
| DCC3491 | Mrs7591 | Novel Partial Agonist of Human and Mouse A3 Adenosine Receptors (Ki = 10.9/17.8 nM, at human/mouse A3AR) |
|
| DCC3492 | Mrs7799 | Novel highly potent A3 adenosine receptor (A3AR) antagonist with Kd values (nM): 0.55 (human), 3.74 (mouse), and 2.80 (rat) |
|
| DCC3493 | Mrt-68601 Hydrochloride | Potent inhibitor of TANK-binding kinase-1 (TBK1)/IKKepislon kinases |
|
| DCC3494 | Mrt-92 Hydrochloride | Novel inhibitor of Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor |
|
| DCC3495 | Mrz-8676 | Novel, selective, orally bioavailable, negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5) |
|
| DCC3496 | ms0017509 | Inhibitor of DNA damage repair |
|
| DCC3497 | ms0019266 | Novel inhibitor of DNA damage repair |
|
| DCC3498 | Ms2126 | Novel inhibitor of Human p53 and CREB Binding Protein (CREBBP) interaction |
|
| DCC3499 | Ms2177 | Novel potent and selective SETD8 inhibitor |
|
| DCC3500 | Ms2i6a | Mitochondrial tRNA-specific modification, regulating efficient mitochondrial translation and energy metabolism in mammals |
|
| DCC3501 | Msc2524070 | Novel potent tankyrase (TNKS) inhibitor (EC 50 : 2 nM) |
|
| DCC3502 | Msc-4381 | Novel inhibitor of SLC16A3 |
|
| DCC3503 | Msd-496486311 | Novel potent and selective PI3Kδ inhibitor |
|
| DCC3504 | Msk-195 | Potent TRPV1 agonist |
|
